#complement — Saturday, May 02, 2026 (1 items)
| 0 | 💬 0 |
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.
(linkinghub.elsevier.com)
|
The Lancet 2026-05-02 | #clinical trial #rnai #autoimmunity #complement #myasthenia gravis |